Evofem Biosciences Inc EVFM:OTC Pink - Current Information

Set AlertOptionsStreaming Charts
Last Price$0.46NASDAQ Previous Close - as of 4:00PM ET 8/11/22

Today's Change-0.02(3.83%)
Bid (Size)$0.42 (5,000)
Ask (Size)$0.46 (2,500)
Day Low / High$0.39 - 0.48
Volume7.3 M
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View IndustryPeer Comparison as of 08/11/2022

Timeframe
 

Evofem Biosciences Inc ( OTC Markets Group Inc - Current Information )

Price: $0.46
Change: -0.02 (3.83%)
Volume: 7.3 M
4:00PM ET 8/11/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Stealth BioTherapeutics Corp ( NASDAQ )

Price: $0.30
Change: -0.002 (0.75%)
Volume: 173.9 K
3:59PM ET 8/11/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Eloxx Pharmaceuticals Inc ( NASDAQ )

Price: $0.27
Change: +0.004 (1.52%)
Volume: 63.6 K
3:54PM ET 8/11/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Aptevo Therapeutics Inc ( NASDAQ )

Price: $4.40
Change: -0.08 (1.79%)
Volume: 182.3 K
4:00PM ET 8/11/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

ENDRA Life Sciences Inc ( NASDAQ )

Price: $0.34
Change: -0.007 (2.03%)
Volume: 224.00
3:58PM ET 8/11/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

Evofem Biosciences Updates on Phase 3 Trial of Chlamydia, Gonorrhea Infection in Women: Shares Rise
12:41PM ET 8/01/2022 MT Newswires

Evofem Biosciences (EVFM) said Monday the last subject has completed her last visit in the company's phase 3 trial of Phexxi for the prevention of...

Top Premarket Gainers
8:00AM ET 7/29/2022 MT Newswires

ThermoGenesis (THMO) shares surged 70% after the company disclosed in a regulatory filing that it has secured an amendment to its convertible promissory...

--Morgan Stanley Adjusts Price Target for Evofem Biosciences to $0.75 From $2, Maintains Underweight Rating
4:07PM ET 7/14/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Evofem Biosciences Receives New US Patent for Contraceptive Gel
10:26AM ET 6/30/2022 MT Newswires

Evofem Biosciences (EVFM) said Thursday it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering the...

View all Commentary and Analysis

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2022 Results - Earnings Call Transcript
11:27PM ET 8/04/2022 Seeking Alpha

Circling Back On Agile Therapeutics
10:57AM ET 7/13/2022 Seeking Alpha

Evofem: Desperate Times, Roe v. Wade To The Rescue?
1:42PM ET 7/07/2022 Seeking Alpha

Evofem Biosciences: An Evaluation
1:48PM ET 7/06/2022 Seeking Alpha

Company Profile

Business DescriptionEvofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA. View company web site for more details
Address12400 High Bluff Drive
San Diego, California 92130
Phone+1.858.550.1900
Number of Employees30
Recent SEC Filing08/10/20228-K
Chairman, President & Chief Executive OfficerSaundra L. Pelletier
Chief Financial OfficerJustin J. File
Head-Medical AffairsBrandi Howard
Senior Director-Information TechnologyBret Henning

Company Highlights

Price Open$0.39
Previous Close$0.46
52 Week Range$0.28 - 14.61
Market Capitalization$83.8 M
Shares Outstanding182.2 M
Sector
Industry
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$16.72
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-1,676.29%
Return on Equity279.34%